CD40: An upstream master switch for endothelial cell activation uncovered by RNAi-coupled transcriptional profiling

Blood

Volumn 112, Issue 9, 2008, Pages 3624-3637

  Pluvinet, Raquel ^a   Olivar, Rut ^a   Krupinski, Jerzy ^b   Herrero Fresneda, Inmaculada ^a   Luque, Anna ^b   Torras, Joan ^a   Cruzado, Josep M ^a   Grinyó, Josep M ^a   Sumoy, Lauro ^c   Aran, Josep M ^a  

^a HOSPITAL DURAN I REYNALS   (Spain)

^b Stroke Unit

^c CENTRE FOR GENOMIC REGULATION CRG   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; RETINOIC ACID INDUCIBLE PROTEIN I; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 3; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; APLN PROTEIN, HUMAN; AUTACOID; SIGNAL PEPTIDE; SMALL INTERFERING RNA;

ADAPTIVE IMMUNITY; ARTICLE; CELL ACTIVATION; CELL ADHESION; CELL FATE; CELL METABOLISM; CELL MOTILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; EXPOSURE; GENE; GENE CONTROL; GENETIC TRANSCRIPTION; HEMOSTASIS; HUMAN; HUMAN CELL; IMMUNOPATHOLOGY; INNATE IMMUNITY; MOLECULAR INTERACTION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STRESS; TRANSCRIPTION REGULATION; UNINDEXED SEQUENCE; UPREGULATION; ANIMAL; BROWN NORWAY RAT; CELL COMMUNICATION; CELL CULTURE; COCULTURE; DNA MICROARRAY; DRUG ANTAGONISM; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; KIDNEY TRANSPLANTATION; LEUKEMIA CELL LINE; LYMPHOCYTE ACTIVATION; METABOLISM; RAT; T LYMPHOCYTE; WISTAR RAT;

ANIMALS; ANTIGENS, CD40; CD40 LIGAND; CELL COMMUNICATION; CELLS, CULTURED; COCULTURE TECHNIQUES; ENDOTHELIAL CELLS; GENE EXPRESSION PROFILING; HUMANS; INFLAMMATION MEDIATORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; JURKAT CELLS; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; MAP KINASE SIGNALING SYSTEM; NF-KAPPA B; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RATS; RATS, INBRED BN; RATS, WISTAR; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 55749085268     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-03-143305     Document Type: Article

References (65)

1. Schönbeck U, Libby P. The CD40/CD154 receptor/ ligand dyad. Cell Mol Life Sci. 2001;58:4-43.
2. Banchereau J, Bazan F, Blanchard D, et al. The CD40 antigen and its ligand. Annu Rev Immunol. 1994;12:881-922.
3. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67:2-17.
4. Pullen SS, Dang TT, Crute JJ, Kehry MR. CD40 signaling through tumor necrosis factor receptorassociated factors (TRAFs): binding site specificity and activation of downstream pathways by distinct TRAFs. J Biol Chem. 1999;274:14246-14254.
5. Schönbeck U, Libby P. CD40 signaling and plaque instability. Circ Res. 2001;89:1092-1103.
6. Chess L. Blockade of the CD40L/CD40 pathway. In: Austen KF, Burakoff SJ, Rosen FS, Strom TB, eds. Therapeutic Immunology. 2nd ed. 2001:441-456.
7. Boumpas DT, Furie R, Manzi S, et al. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum. 2003;48:719-727.
8. Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand [letter]. Nat Med. 2000;6:114.
9. Pluvinet R, Petriz J, Torras J, et al. RNA-imediated silencing of CD40 prevents leukocyte adhesion on CD154-activated endothelial cells. Blood. 2004;104:3642-3646.
10. Lederman S, Yellin MJ, Krichevsky A, Belko J, Lee JJ, Chess L. Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help). J Exp Med. 1992;175:1091-1101.
11. National Center for Biotechnology Information. Gene Expression Omnibus (GEO). http://www. ncbi.nlm.nih.gov/geo. Accessed February 21, 2008.
12. Saeed AI, Sharov V, White J, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003;34:374-378.
13. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledgebased approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545-15550.
14. Massachusetts Institute of Technology. Molecular Signatures Database (MSigDB). http://www. broad.mit.edu/gsea/msigdb/index.jsp. Accessed October 3, 2006.
15. Stary HC, Chandler AB, Dinsmore RE, et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995; 92:1355-1374.
16. Herrero-Fresneda I, Franquesa M, Torras J, et al. Role of cold ischemia in acute rejection: characterization of a humoral-like acute rejection in experimental renal transplantation. Transplant Proc. 2005;37:3712-3715.
17. Phipps RP. Atherosclerosis: the emerging role of inflammation and the CD40-CD40 ligand system. Proc Natl Acad Sci U S A. 2000;97:6930-6932.
18. National Center for Biotechnology Information. UniGene. http://www.ncbi.nlm.nih.gov/sites/ entrez?dbunigene. Accessed June 11, 2007.
19. National Center for Biotechnology Information. GenBank. http://www.ncbi.nlm.nih.gov/Genbank. Accessed June 11, 2007.
20. Barrans JD, Allen PD, Stamatiou D, Dzau VJ, Liew CC. Global gene expression profiling of endstage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. Am J Pathol. 2002;160:2035-2043.
21. Türeci O, Bian H, Nestle FO, et al. Cascades of transcriptional induction during dendritic cell maturation revealed by genome-wide expression analysis. FASEB J. 2003;17:836-847.
22. Kleinz MJ, Davenport AP. Emerging roles of apelin in biology and medicine. Pharmacol Ther. 2005;107:198-211.
23. Lee DK, Cheng R, Nguyen T, et al. Characterization of apelin, the ligand for the APJ receptor. J Neurochem. 2000;74:34-41.
24. Medhurst AD, Jennings CA, Robbins MJ, et al. Pharmacological and immunohistochemical characterization of the APJ receptor and its endogenous ligand apelin. J Neurochem. 2003;84:1162-1172.
25. Herrero-Fresneda I, Gulías O, Franquesa M, et al. Local gene therapy with anti-CD40 siRNA plus rapamycin prolongs survival and decreases posttransplant renal acute rejection [abstract]. Transpl Int. 2007;20:s2. Abstract O230.
26. Büchner K, Henn V, Grafe M, de Boer OJ, Becker AE, Kroczek RA. CD40 ligand is selectively expressed on CD4+ T cells and platelets: implications for CD40-CD40L signalling in atherosclerosis. J Pathol. 2003;201:288-295.
27. Chi JT, Chang HY, Wang NN, Chang DS, Dunphy N, Brown PO. Genomewide view of gene silencing by small interfering RNAs. Proc Natl Acad Sci U S A. 2003;100:6343-6346.
28. Semizarov D, Frost L, Sarthy A, Kroeger P, Halbert DN, Fesik SW. Specificity of short interfering RNA determined through gene expression signatures. Proc Natl Acad Sci U S A. 2003;100: 6347-6352.
29. Semizarov D, Kroeger P, Fesik S. siRNA-mediated gene silencing: a global genome view. Nucleic Acids Res. 2004;32:3836-3845.
30. Dadgostar H, Zarnegar B, Hoffmann A, et al. Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes. Proc Natl Acad Sci U S A. 2002;99:1497-1502.
31. Gricks CS, Zahrieh D, Zauls AJ, et al. Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells. Blood. 2004;104:4002-4009.
32. Basso K, Klein U, Niu H, et al. Tracking CD40 signaling during germinal center development. Blood. 2004;104:4088-4096.
33. Lang I, Pabst MA, Hiden U, et al. Heterogeneity of microvascular endothelial cells isolated from human term placenta and macrovascular umbilical vein endothelial cells. Eur J Cell Biol. 2003;82: 163-173.
34. Ribatti D, Nico B, Vacca A, Roncali L, Dammacco F. Endothelial cell heterogeneity and organ specificity. J Hematother Stem Cell Res. 2002;11:81-90.
35. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352: 1685-1695.
36. Horrevoets AJ, Fontijn RD, van Zonneveld AJ, de Vries CJ, ten Cate JW, Pannekoek H. Vascular endothelial genes that are responsive to tumor necrosis factor-alpha in vitro are expressed in atherosclerotic lesions, including inhibitor of apoptosis protein-1, stannin, and two novel genes. Blood. 1999;93:3418-3431.
37. Zhou J, Jin Y, Gao Y, et al. Genomic-scale analysis of gene expression profiles in TNF-alpha treated human umbilical vein endothelial cells. Inflamm Res. 2002;51:332-341.
38. Viemann D, Goebeler M, Schmid S, et al. Transcriptional profiling of IKK2/NF-kappa B- and p38 MAP kinase-dependent gene expression in TNF-alphastimulated primary human endothelial cells. Blood. 2004;103:3365-3373.
39. Sana TR, Janatpour MJ, Sathe M, McEvoy LM, McClanahan TK. Microarray analysis of primary endothelial cells challenged with different inflammatory and immune cytokines. Cytokine. 2005; 29:256-269.
40. Francis DA, Karras JG, Ke XY, Sen R, Rothstein TL. Induction of the transcription factors NF-kappa B, AP-1 and NF-AT during B cell stimulation through the CD40 receptor. Int Immunol. 1995;7:151-161.
41. Bates PW, Miyamoto S. Expanded nuclear roles for IkappaBs. Sci STKE. 2004 Oct 12;2004(254): pe48.
42. Warton K, Foster NC, Gold WA, Stanley KK. A novel gene family induced by acute inflammation in endothelial cells. Gene. 2004;342:85-95.
43. Pearson LL, Castle BE, Kehry MR. CD40-mediated signaling in monocytic cells: upregulation of tumor necrosis factor receptorassociated factor mRNAs and activation of mitogen-activated protein kinase signaling pathways. Int Immunol. 2001;13:273-283.
44. Grewal IS, Flavell RA. CD40 and CD154 in cellmediated immunity. Annu Rev Immunol. 1998;16: 111-135.
45. Marelli-Berg FM, Jarmin SJ. Antigen presentation by the endothelium: a green light for antigenspecific T cell trafficking? Immunol Lett. 2004;93: 109-113.
46. Meylan E, Tschopp J. Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. Mol Cell. 2006;22:561-569.
47. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol. 2006;7:131-137.
48. Honda K, Takaoka A, Taniguchi T. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity. 2006;25:349-360.
49. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev. 2001;14:778-809.
50. Silverman RH. Viral encounters with 2′,5′ -oligoadenylate synthetase and RNase L during the interferon antiviral response. J Virol. 2007;81: 12720-12729.
51. Degrandi D, Konermann C, Beuter-Gunia C, et al. Extensive characterization of IFN-induced GTPases mGBP1 to mGBP10 involved in host defense. J Immunol. 2007;179:7729-7740.
52. Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol. 2005;23: 307-336.
53. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med. 2007;13: 543-551.
54. Andreakos E, Foxwell B, Feldmann M. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol Rev. 2004; 202:250-265.
55. Kleinz MJ, Davenport AP. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept. 2004;118:119-125.
56. Kleinz MJ, Skepper JN, Davenport AP. Immunocytochemical localisation of the apelin receptor, APJ, to human cardiomyocytes, vascular smooth muscle and endothelial cells. Regul Pept. 2005; 126:233-240.
57. Schönbeck U, Sukhova GK, Shimizu K, Mach F, Libby P. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci U S A. 2000;97:7458-7463.
58. Ishida J, Hashimoto T, Hashimoto Y, et al. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem. 2004;279: 26274-26279.
59. Tatemoto K, Takayama K, Zou MX, et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept. 2001;99:87-92.
60. Hus-Citharel A, Bouby N, Frugiere A, Bodineau L, Gasc JM, Llorens-Cortes C. Effect of apelin on glomerular hemodynamic function in the rat kidney. Kidney Int. 2008;74:486-494.
61. 't Hart BA, Hintzen RQ, Laman JD. Preclinical assessment of therapeutic antibodies against human CD40 and human interleukin-12/23p40 in a nonhuman primate model of multiple sclerosis. Neurodegener Dis. 2008;5:38-52.
62. Haubitz M. Exploring new territory: the move towards individualised treatment. Lupus. 2007;16: 227-231.
63. Lutgens E, Lievens D, Beckers L, Donners M, Daemen M. CD40 and its ligand in atherosclerosis. Trends Cardiovasc Med. 2007;17:118-123.
64. Vishnevetsky D, Kiyanista VA, Gandhi PJ. CD40 ligand: a novel target in the fight against cardiovascular disease. Ann Pharmacother. 2004;38: 1500-1508.
65. Burkhart C, Heusser C, Morris RE, et al. Pharmacodynamics in the development of new immunosuppressive drugs. Ther Drug Monit. 2004;26: 588-592.